Skip to Main Content

Specialists Fact Sheets Departments Clinical Trials News Patient Tools For Medical Professionals

Clinical Trials

Discover the future of medicine today. Yale Medicine currently offers 691 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.

For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.

What is a Clinical Trial?
FAQs About Clinical Trials
About YCCI

Filter By

Category

No items

Gender

Male(1)

Female(1)

All Genders(1)

Patient Age

1 month

2 months

3 months

4 months

5 months

6 months

7 months

8 months

9 months

10 months

11 months

1 year

2 years

3 years

4 years

5 years

6 years

7 years

8 years

9 years

10 years

11 years

12 years

13 years

14 years

15 years

16 years

17 years

18 years

19 years

20 years

21 years

22 years

23 years

24 years

25 years

26 years

27 years

28 years

29 years

30 years

31 years

32 years

33 years

34 years

35 years

36 years

37 years

38 years

39 years

40 years

41 years

42 years

43 years

44 years

45 years

46 years

47 years

48 years

49 years

50 years

51 years

52 years

53 years

54 years

55 years

56 years

57 years

58 years

59 years

60 years

61 years

62 years

63 years

64 years

65 years

66 years

67 years

68 years

69 years

70 years

71 years

72 years

73 years

74 years

75 years

76 years

77 years

78 years

79 years

80 years

81 years

82 years

83 years

84 years

85 years

86 years

87 years

88 years

89 years

90 years

Study Location

No items

For healthy volunteers(1)

15 Results

Sort By

Relevant
Newest
Oldest

Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
- Kidney Cancer
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
- Breast Cancer
Impact of cancer immunotherapy on the kidneys
- Kidney Cancer
- Supportive Care
- Non-Therapeutic
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
- Lung Cancer
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) in Patients With Advanced Solid Organ Malignancies
- Kidney Cancer
- Melanoma
Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours
- Phase 1 Cancers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors
- Phase 1 Cancers
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors
- Phase 1 Cancers
R3767-ONC-22122: A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatilimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma
- Melanoma

Results per Page

10
20
50

1-10 of 15 Results

About Us
Contact Us
Donate
Referring Doctors
Clinical Keywords

333 Cedar St.

New Haven, CT 06510

Yale School of Medicine
Yale University

Terms & Privacy Policies
Accessibility at YSM
Patient Rights
HIPAA at Yale
Non-discrimination Statement

Copyright 2026 Yale Medicine